Holen Sie sich die Stockscreener-App
55.97
1.69%
0.9703
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb -- Barrons.com - Moomoo
Bristol Myers Follows Novartis, Sues Arkansas Over Pharmacy Law - Bloomberg Law News
Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE - Ad-hoc-news.de
Opdivo from Bristol-Myers Squibb Co.immunotherapy mainstay with new combo data - Ad-hoc-news.de
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies - Insider Monkey
Bristol Myers Squibb weighs dividend reset, shares trade near recent lows - AD HOC NEWS
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb Company (BMY) Stock Analysis: Exploring the 16.81% Upside Potential for Investors - DirectorsTalk Interviews
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey
Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Valuation: PE, PB & Fair Value Analysis - TradingKey
CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bristol-Myers Squibb Company: Target Price Consensus and Analysts Recommendations | BMY | US1101221083 - marketscreener.com
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance
Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol-Myers Squibb Co (BMY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb declares $0.63 quarterly dividend By Investing.com - Investing.com Canada
Bristol-Myers Squibb Co (CELG_r) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries - PR Newswire UK
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada - PR Newswire Canada
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol-Myers Squibb Co (BMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio? - Yahoo Finance
Bristol-Myers Squibb—ad spending, facts and profile - Ad Age
Psoriasis around the world - Bristol Myers Squibb
David Elkins - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion - simplywall.st
Chris Boerner, Board Chair and Chief Executive Officer - Bristol Myers Squibb
Cari Gallman - Bristol Myers Squibb
Karin Shanahan - Bristol Myers Squibb
Technologies - Bristol Myers Squibb
BMY Faces Headline Risk Amid Medicare Drug Price Negotiation Pro - GuruFocus
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb - Yahoo Finance
Panagora Asset Management Inc. Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 10.41% Upside in the Healthcare Giant - DirectorsTalk Interviews
Bristol-Myers Squibb Stock (US1078421011): Dividend Safety Under the Microscope - AD HOC NEWS
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool
PIMCO RAE US Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Large Cap Core Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Company $BMY Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Mike Kelly sells shares in Bristol-Myers Squibb and Comcast, buys Southeast Energy Authority bonds - Investing.com Canada
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? - Yahoo Finance
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today - Yahoo Finance
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):